AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US

AstraZeneca Plc AZN said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.

  • The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would be announced in the coming weeks.
  • The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy.
  • In December, the antibody showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study. 
  • The FDA last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.
  • The Company said it is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure.
  • Price Action: AZN shares are -0.2% at $58.39 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechGovernmentNewsHealth CareContractsGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!